Breast cancer is a complex and heterogeneous disease with substantial improvements in clinical outcomes over the years. However, selecting the optimal treatment remains challenging, especially beyond standard biomarkers (e.g., ER, PR, HER2), which often provide limited predictive value. Functional precision medicine can complement molecular profiling by measuring direct ex vivo drug responses to guide more effective, individualized treatments.
Optim.AI™ is a combinatorial functional precision medicine platform that integrates high throughput drug screening with AI-driven analytics to identify effective mono- and combination therapies.
In this study, we evaluated the technical feasibility and potential clinical utility of Optim.AI™ in primary and metastatic breast cancer using patient-derived organoids (PDOs).